Search
Hydroxyamphetamine
go.drugbank.com/drugs/DB09352ApprovedThe main use of hydroxyamphetamines as eye drops is the diagnosis of Horner's syndrome which is characterized by nerve lesions.
Avutometinib
go.drugbank.com/drugs/DB15254ApprovedInvestigational[A273948] Avutometinib was approved by the US FDA in May 2025 in a co-package alongside [defactinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian cancer
Omalizumab
go.drugbank.com/drugs/DB00043ApprovedInvestigationalBy binding to IgE and neutralizing it, omalizumab reduces free IgE levels and prevents IgE from binding to its receptors on immune cells.
Methadone
go.drugbank.com/drugs/DB00333ApprovedInvestigational[A497,A5344] Specifically by inhibiting the NMDA receptor, methadone dampens a major excitatory pain pathway within the central nervous system. … Use of OAT is also intended to lead to social stabilization by reducing crime rates, incarceration, use of illicit opioids such as [heroin] or [fentanyl], and ultimately marginalization.
Pradofloxacin
go.drugbank.com/drugs/DB11453ExperimentalVet approvedIt was approved by the European Commission in April 2011 for bacterial infections in dogs and cats. … Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH.
Lymecycline
go.drugbank.com/drugs/DB00256ApprovedInvestigationalWithdrawnIt is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries.
Sipavibart
go.drugbank.com/drugs/DB21908ApprovedInvestigational[A274098] It works by binding to the SARS-CoV-2 spike protein receptor binding domain (RBD), neutralize the virus and preventing its entry into the host cell.
Exemestane
go.drugbank.com/drugs/DB00990ApprovedInvestigationalExemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the ...
Benidipine
go.drugbank.com/drugs/DB09231Investigational[A31948] It was originated in Japan by Kyowa Hakko, it is submitted for FDA approval and it is currently available in some Asian countries like India and Japan.[L1385, L1386]
Coagulation factor VII human
go.drugbank.com/drugs/DB13150ApprovedInvestigationalCoagulation factor VII is human serine protease type enzyme that is involved in the extrinsic coagulation cascade which results in blood clotting.